These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 33466394)

  • 61. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer.
    Grifantini R; Taranta M; Gherardini L; Naldi I; Parri M; Grandi A; Giannetti A; Tombelli S; Lucarini G; Ricotti L; Campagnoli S; De Camilli E; Pelosi G; Baldini F; Menciassi A; Viale G; Pileri P; Cinti C
    J Control Release; 2018 Jun; 280():76-86. PubMed ID: 29733876
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical application of genetics in management of colorectal cancer.
    Kim ER; Kim YH
    Intest Res; 2014 Jul; 12(3):184-93. PubMed ID: 25349592
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular therapy of colorectal cancer: progress and future directions.
    Weng W; Feng J; Qin H; Ma Y
    Int J Cancer; 2015 Feb; 136(3):493-502. PubMed ID: 24420815
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
    Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
    Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer.
    Patnaik S; Anupriya
    Front Pharmacol; 2019; 10():588. PubMed ID: 31244652
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Colorectal carcinogenesis--update and perspectives.
    Raskov H; Pommergaard HC; Burcharth J; Rosenberg J
    World J Gastroenterol; 2014 Dec; 20(48):18151-64. PubMed ID: 25561783
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer.
    Shi L; Xu Y; Feng M
    Dig Dis Sci; 2023 Feb; 68(2):370-379. PubMed ID: 36575326
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ezrin expression and cell survival regulation in colorectal cancer.
    Leiphrakpam PD; Rajput A; Mathiesen M; Agarwal E; Lazenby AJ; Are C; Brattain MG; Chowdhury S
    Cell Signal; 2014 May; 26(5):868-79. PubMed ID: 24462708
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 70. Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer.
    Nordgaard C; Doll S; Matos ALSA; Høeberg M; Kazi JU; Friis S; Stenvang J; Rönnstrand L; Mann M; Manuel Afonso Moreira J
    Mol Oncol; 2019 Dec; 13(12):2646-2662. PubMed ID: 31545548
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer.
    Kocoglu H; Velibeyoglu FM; Karaca M; Tural D
    World J Gastrointest Oncol; 2016 Jan; 8(1):1-7. PubMed ID: 26798432
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 73. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.
    Solier S; Zhang YW; Ballestrero A; Pommier Y; Zoppoli G
    Curr Cancer Drug Targets; 2012 May; 12(4):356-71. PubMed ID: 22385513
    [TBL] [Abstract][Full Text] [Related]  

  • 74. MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics.
    Yamamoto H; Mori M
    Adv Exp Med Biol; 2016; 937():239-47. PubMed ID: 27573904
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer.
    Pourdavoud P; Pakzad B; Mosallaei M; Saadatian Z; Esmaeilzadeh E; Alimolaie A; Shaygannejad A
    Mol Biol Rep; 2020 Dec; 47(12):9913-9920. PubMed ID: 33130965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Monoclonal Antibodies in Cancer Therapy.
    Zahavi D; Weiner L
    Antibodies (Basel); 2020 Jul; 9(3):. PubMed ID: 32698317
    [TBL] [Abstract][Full Text] [Related]  

  • 77. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.
    Kumar A; Gautam V; Sandhu A; Rawat K; Sharma A; Saha L
    World J Gastrointest Surg; 2023 Apr; 15(4):495-519. PubMed ID: 37206081
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.